|
|
The High Yield
This week's best high-income pick
|
|
OBDCBlue Owl Capital — 11.2% yield, but I need to update you
|
OBDC is a BDC — a business development company. Think of it as a company that makes loans to mid-size private businesses, kind of like a bank but without the branches. Investors get a cut of the interest income. OBDC pays $0.31 per quarter, and at $11.10 a share, that's an 11.2% yield. $1,120 a year on every $10,000. About $280 every 90 days.
I need to update you on earlier this week. Q1 2026 net investment income — the cash OBDC earns from its loans — came in at $0.32 per share. That just barely covers the $0.31 payout. Coverage sits around 103%. The underlying portfolio value (called NAV, or net asset value) slipped from $14.81 to $14.41. The $300 million buyback program helps support the share price, and Q2 earnings are due soon. I own this. I'm not selling. But I'm not adding until I see Q2 numbers.
|
|
Yield: 11.2%
|
$10K invested = $1,120/yr
|
Paid: Quarterly
|
|
|
|
|
|
Dividend Aristocrats
This week's best blue-chip legacy payer
|
|
ABBVAbbVie — 54 years of raises and still going
|
AbbVie went ex-dividend on July 15 — meaning if you owned shares by then, you're locked in for the next $1.73 quarterly payment. That's $6.92 a year. At $244 a share, the yield is 2.84%. Your $10,000 becomes $284 a year.
Here's why AbbVie is the Aristocrat pick of the week: 54 consecutive years of dividend increases when you include the Abbott Labs legacy. AbbVie spun off from Abbott in 2013 and kept the streak alive. Humira's patent cliff was the big worry — and it was real — but Skyrizi and Rinvoq are replacing that revenue faster than most analysts expected. Management guided for over $14 in adjusted earnings per share this year. The payout ratio sits around 50%, which gives them room to keep raising. Risk: drug pipelines carry clinical trial uncertainty, and if the next-gen drugs stumble, the math changes. But 54 years of raises earn a lot of benefit of the doubt.
|
|
Yield: 2.84%
|
$10K invested = $284/yr
|
Paid: Quarterly
|
|
|
|
|
|
Dividend Growth Stars
This week's fastest-rising income builder
|
|
SNASnap-on — 14% raise and 87 years without a miss
|
Snap-on raised its dividend 14% this year — from $2.14 to $2.44 per quarter. That's $9.76 a year. At $404, the yield is 2.42%, and your $10,000 earns $242 a year.
Here's what makes Snap-on my growth pick of the week: they haven't missed a single dividend payment since 1939. Eighty-seven years. Through World War II, Korea, Vietnam, stagflation, the dot-com crash, the financial crisis, COVID — 87 years straight. The company makes professional-grade tools and diagnostics equipment for mechanics. These aren't discretionary purchases. When your wrench set costs $3,000, it's because you need it to do your job.
The payout ratio is well below 50%, so there's room for another double-digit raise next year. Risk: SNA trades near its all-time high of $414 and carries a premium valuation. If the economy slows, tool demand could soften. But that 14% hike tells me management sees strong earnings ahead.
|
|
Yield: 2.42%
|
$10K invested = $242/yr
|
Paid: Quarterly
|
|
|
|
|
|